Vaccine order boosts Bavarian Nordic after cancer drug flop

Share this post

COPENHAGEN (Reuters) – Biotech group Bavarian Nordic said it expected to win more contracts in the United States for its smallpox vaccine after securing an order from the U.S. government stockpile.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply